Adverum Biotechnologies Announces Appointment of Heikki Jouttijärvi as Vice President of Manufacturing - Seite 2
About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of
its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more
information, please visit www.adverum.com.
Lesen Sie auch
Forward-looking Statements
Statements contained in this press release regarding the events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include but are not limited to statements regarding: Adverum’s advancements of current clinical trials, and its plans for later-stage clinical trials and growth
and expansion of its manufacturing capabilities; and Adverum’s expectations as to the benefits it expects from the addition of Mr. Jouttijärvi. Actual results could differ materially from
those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include risks inherent to, without limitation: Adverum’s novel technology, which makes it
difficult to predict the time and cost of product candidate development and obtaining regulatory approval; the results of early clinical trials not always being predictive of future results; the
potential for future complications or side effects in connection with use of ADVM-022; obtaining regulatory approval for gene therapy product candidates; enrolling patients in clinical trials;
reliance on third parties for conducting the OPTIC and INFINITY trials and vector production; the effects of the COVID-19 pandemic on the company’s operations and on the company’s ongoing clinical
trials; and ability to fund operations through completion of the OPTIC and INFINITY trials and thereafter. Risks and uncertainties facing Adverum are described more fully in Adverum’s Form 10-Q
filed with the SEC on May 28, 2020 under the heading “Risk Factors.” All forward-looking statements contained in this press release speak only as of the date on which they were
made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.